RAFAEL HOLDINGS, INC. Deferred Costs and Other Assets
RAFAEL HOLDINGS, INC. (RFL) had Deferred Costs and Other Assets of $1.30 million as of 2022-04-30, per its 10-Q filed 2022-06-14.
Discontinued › Notes › and Other Assets
us-gaap:DeferredCostsAndOtherAssets · last filed 2022-06-14
- 2022-04-30: Deferred Costs and Other Assets $1.30M.
- 2022-01-31: Deferred Costs and Other Assets $1.40M.
- 2021-10-31: Deferred Costs and Other Assets $1.40M.
- 2021-07-31: Deferred Costs and Other Assets $1.50M.
| Period end | Deferred Costs and Other Assets | Deferred Costs and Other Assets as first filed |
|---|---|---|
| 2022-04-30 | $1.30M 10-Q · filed 2022-06-14 | |
| 2022-01-31 | $1.40M 10-Q · filed 2022-03-17 | |
| 2021-10-31 | $1.40M 10-Q/A · filed 2022-02-28 | |
| 2021-07-31 | $1.50M 10-Q · filed 2022-06-14 | |
| 2021-04-30 | $1.40M 10-Q · filed 2021-06-14 | |
| 2020-07-31 | $1.50M 10-K · filed 2021-10-18 | $1.40M 10-Q · filed 2021-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |